Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546544 | 1.00 | ALDH1A1 (0.45) | ALDH1A1GAAHSD17B10LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28520452 | 0.99 | ALDH1A1 (0.44) | ALDH1A1GAAHSD17B10LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28270682 | 0.99 | ALDH1A1 (0.44) | ALDH1A1GAAHSD17B10LMNAMEN1 | |
| SCHEMBL31753168 | 0.87 | SLC7A5 (0.42) | ALDH1A1GAAHSD17B10SLC7A5CA1 | |
| SCHEMBL16978741 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10LMNAMEN1 | |
| SCHEMBL12718972 | 0.85 | SLC7A5 (0.49) | ALDH1A1GAAHSD17B10MEN1KMT2A | |
| SCHEMBL879316 | 0.85 | SLC7A5 (0.49) | ALDH1A1GAAHSD17B10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28435547 | 0.84 | ALDH1A1 (0.48) | ALDH1A1GAAHSD17B10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28435545 | 0.84 | ALDH1A1 (0.48) | ALDH1A1GAAHSD17B10MEN1KMT2A | |
| SCHEMBL15441969 | 0.84 | SLC7A5 (0.57) | ALDH1A1GAAHSD17B10SLC7A5GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776984-A | Preparation method of ritalst intermediate | 浙江博崤生物制药有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117776984-B | Litaset in Litaset Process for the preparation of intermediates | 浙江博崤生物制药有限公司 | 2026-04-03 | — | — | CN | disclosed |
| CN-112272665-B | Process for preparing ritalst | 欧伦股份公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117776984-A | Preparation method of ritalst intermediate | 浙江博崤生物制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117776984-A | Preparation method of ritalst intermediate | 浙江博崤生物制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| US-11498917-B2 | Process for the preparation of lifitegrast | OLON S.P.A. (IT) | 2022-11-15 | — | — | US | disclosed |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.P.A. (IT) | 2021-08-12 | — | — | US | disclosed |
| EP-3807268-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.p.A. (IT) | 2021-04-21 | — | — | EP | disclosed |
| CN-112272665-A | Process for preparing sitagliptin | 欧伦股份公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2019053607-A1 | PROCESS FOR PREPARATION OF LIFITEGRAST | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2019-03-21 | — | — | WO | disclosed |
| US-9085553-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | SARcode Bioscience, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498917-B2 | Process for the preparation of lifitegrast | LIFR, FLT3, F12 | ALDH1A1 2375/4885GAA 2413/4885HSD17B10 4209/4885 |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | ALDH1A1 62/4885GAA 490/4885HSD17B10 3420/4885 |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, FLT3, F12 | ALDH1A1 2375/4885GAA 2413/4885HSD17B10 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.